Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders.
Biogen cuts almost one-third of Reata’s staff following $7B buyout
Biogen made a big M&A splash in July with its $7.3 billion buyout of Reata Pharmaceuticals, which had just secured FDA approval for a rare
October 12, 2023